Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ovary syndrome
- 1 April 1995
- journal article
- Published by Elsevier in Fertility and Sterility
- Vol. 63 (4) , 742-746
- https://doi.org/10.1016/s0015-0282(16)57475-5
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?American Journal of Obstetrics and Gynecology, 1992
- From somatostatin to Sandostatin®: Pharmacodynamics and pharmacokineticsMetabolism, 1992
- From somatostatin to Sandostatin®: History and chemistryMetabolism, 1992
- On the Paradox of Insulin-Induced Hyperandrogenism in Insulin-Resistant StatesEndocrine Reviews, 1991
- Specific binding sites for insulin-like growth factor I in the ovarian stroma of women with polycystic ovarian disease and stromal hyperthecosisAmerican Journal of Obstetrics and Gynecology, 1990
- An Abnormality of the Growth Hormone/Insulin-Like Growth Factor-I Axis in Women with Polycystic Ovary Syndrome*Journal of Clinical Endocrinology & Metabolism, 1990
- Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndromeThe Lancet, 1990
- The central role of obesity (hyperinsulinemia) in the pathogenesis of the polycystic ovary syndromeAmerican Journal of Obstetrics and Gynecology, 1989
- Distribution and Characterization of Insulin and Insulin-like Growth Factor I Receptors in Normal Human Ovary*Journal of Clinical Endocrinology & Metabolism, 1985
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982